Canagliflozin
Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively[1].
Product Specifications
CAS Number
[842133-18-0]
Product Name Alternative
JNJ 28431754
UNSPSC
12352005
Hazard Statement
H318, H361
Target
SGLT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Metabolic Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Canagliflozin.html
Purity
99.99
Solubility
DMSO : ≥ 50 mg/mL
Smiles
FC1=CC=C(C2=CC=C(CC3=C(C=CC([C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)=C3)C)S2)C=C1
Molecular Formula
C24H25FO5S
Molecular Weight
444.52
Precautions
H318, H361
References & Citations
[1]Matsuda H, et al. Roles of capsaicin-sensitive sensory nerves, endogenous nitric oxide, sulfhydryls, and prostaglandins in gastroprotection by momordin Ic, an oleanolic acid oligoglycoside, on ethanol-induced gastric mucosal lesions in rats. Life Sci. 1999;65 (2) :PL27-32.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
SGLT2
Citation 01
Acta Pharmacol Sin. 2024 Dec;45 (12) :2579-2597.|Antioxidants (Basel) . 2023 Mar 30;12 (4) :838.|Antioxidants (Basel) . 2024 Jul 11;13 (7) :831.|Arch Toxicol. 2025 Feb;99 (2) :729-744.|Biochem Biophys Res Commun. 2023 Apr 23:653:53-61.|Biochem Pharmacol. 2018 Jun:152:45-59.|Biochem Pharmacol. 2020 May;175:113856.|Biochim Biophys Acta Mol Cell Res. 2025 Oct 12;1873 (1) :120069.|Biomed Chromatogr. 2016 Oct;30 (10) :1549-55.|Biomed Chromatogr. 2019 Nov;33 (11) :e4663.|Biomed Pharmacother. 2020 Dec;132:110821.|Biomed Pharmacother. 2023 Aug:164:114907.|Biomed Pharmacother. 2023 Mar:159:114228.|Biomed Pharmacother. 2024 Jun 27:177:117044.|Cardiovasc Res. 2021 Dec 17;117 (14) :2794-2806.|Cardiovasc Res. 2023 Oct 24;119 (13) :2368-2381.|Cell Commun Signal. 2024 Nov 7;22 (1) :534.|Commun Biol. 2023 Sep 8;6 (1) :919.|Diabetes. 2025 Feb 11:db240955.|FASEB J. 2025 Jul 31;39 (14) :e70880.|FASEB J. 2025 May 31;39 (10) :e70630.|Front Pharmacol. 2025 Apr 30:16:1573032.|Int Immunopharmacol. 2020 Nov;88:106969.|Int J Med Sci. 2018 Jun 13;15 (9) :937-943. |Int J Mol Sci. 2024 Jul 10;25 (14) :7567.|Int J Mol Sci. 2025 Jan 24;26 (3) :978.|Int J Mol Sci. 2025 Oct 16;26 (20) :10098.|Int J Oncol. 2020 Nov;57 (5) :1223-1233.|J Am Heart Assoc. 2022 Aug 2;11 (15) :e025328.|Mol Cell Endocrinol. 2024 Mar 1:582:112139.|Mol Cell. 2020 Oct 1;80 (1) :87-101.e5.|Mol Med Rep. 2021 Oct;24 (4) :703.|Mol Metab. 2019 Jan:19:1-12.|Mol Oncol. 2023 Nov;17 (11) :2235-2256.|Nat Cancer. 2024 Mar;5 (3) :433-447.|Nat Cell Biol. 2022 Jun;24 (6) :954-967.|Nature. 2018 Aug;560 (7719) :499-503.|Neurotherapeutics. 2023 Dec 19, e00305.|Patent. US20210236501A1.|Research Square Preprint. 2023 Dec 28.|Sci Rep. 2021 Jul 1;11 (1) :13700.|Vascul Pharmacol. 2018 Oct:109:56-71.|J Diabetes Investig. 2025 Aug;16 (8) :1430-1444.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2552916-01 0.01 mg
Recombinant Human Linker for Activation of T-Cells Family Member 2/LAT2 Protein (C-6His)
Ask
View Details